Thus, patients with CLL undergoing treatment with BTK inhibitors may continue to face an elevated risk of SPM because BTK inhibition has potentially deleterious effects on the immune response, and the occurrence of secondary malignancies in CLL and factors contributing to their emergence warrant further investigation. Here, BTK is linked to B-cell chronic lymphocytic leukemia.